Horizon Pharma plc Withdraws Offer to Acquire Depomed, Inc. - Seite 3

Additional Information
This press release does not constitute an offer to buy or solicitation of any offer to sell or vote securities and is for informational purposes only. It relates to the offer previously commenced by Horizon Pharma to exchange each issued and outstanding share of Depomed common stock for 0.95 Horizon Pharma ordinary shares. The offer was intended to be made only through the Tender Offer Statement on Schedule TO or the Prospectus/Offer to Exchange included in the Registration Statement on Form S-4 (File No. 333-206798) (including the Letter of Transmittal and related documents and as amended from time to time, the "Exchange Offer Documents") that Horizon Pharma has filed with the SEC. Horizon Pharma may file additional documents with the SEC in connection with the offer. This press release is not a substitute for any or any registration statement, prospectus, proxy statement, Exchange Offer Document or other documents Horizon Pharma and/or Depomed may file with the SEC in connection with the offer or any other proposed transaction involving Horizon Pharma and Depomed.

Investors and security holders may obtain free copies of the Exchange Offer Documents, and any other related documents filed with the SEC at the SEC's web site at www.sec.gov or by directing a request to Horizon Pharma's Investor Relations department at Horizon Pharma, Inc., Attention: Investor Relations, 520 Lake Cook Road, Suite 520, Deerfield, IL 60015 or to Horizon Pharma's Investor Relations department at 224-383-3400 or by email to [e-mail]. Investors and security holders may obtain free copies of the documents filed with the SEC on Horizon Pharma's website at www.horizonpharma.com under the heading "Investors" and then under the heading "SEC Filings."

Contacts:
Investors:
John Thomas
Executive Vice President, Strategy and Investor Relations
[e-mail]

Tina Ventura
Vice President, Investor Relations
[e-mail]

Dan Burch
MacKenzie Partners, Inc.
212-929-5748
[e-mail]

Bob Marese
MacKenzie Partners, Inc.
212-929-5405
[e-mail]

U.S. Media:
Geoff Curtis
Group Vice President, Corporate Communications
[e-mail]

Daniel Yunger
Kekst and Company
[e-mail]

Ireland Media:
Ray Gordon
Gordon MRM
[e-mail]